Its the core part of popular commercially available anti-obesity drugs like Ozempic, which is often sold pre-loaded into a syringe that patients self-inject with
Over the next few weeks, Im going to be doing a 3-part series, examining GLP-1 receptor agonists
Triple agonists: Retatrutide (GIP/GLP-1/glucagon)
It is the beginning of a commercial cycle that will play out over the next five to seven years, with multiple inflection points: oral formulation launches, international market entries, biosimilar adjacencies, and ongoing price compression driving volume growth
For example, if a person starts taking semaglutide and then experiences chest pain, doctors will look at their medical history, other medications they are taking, and any other possible causes of the chest pain